Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results
Posted inGeneral Surgery news Oncology

Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results

Interim results from the phase 2 PHERFLOT trial show a 48.4% pathological complete response and a 67.7% major pathologic response after four cycles of pembrolizumab, trastuzumab and FLOT in localized HER2‑positive esophagogastric adenocarcinoma; safety was consistent with known profiles.
MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC
Posted innews Oncology Urology

MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC

Final MAGNITUDE results show niraparib combined with abiraterone–prednisone improves radiographic PFS, time to symptomatic progression and delays cytotoxic chemotherapy in HRR‑altered mCRPC (notably BRCA1/2), preserves patient‑reported quality of life, but did not demonstrate a statistically significant overall survival benefit in the primary analysis.
Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
Posted inDermatology news Oncology

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectable cutaneous squamous cell carcinoma.
Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma
Posted innews Oncology

Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma

The randomized phase 1b/2 Morpheus‑Melanoma trial found that tobemstomig (anti‑PD‑1/anti‑LAG‑3 bispecific) produced comparable pathological response rates to nivolumab plus ipilimumab with a substantially improved safety profile in resectable stage III melanoma.
Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
Posted inNeurology news Oncology

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers of delayed onset and longer leptomeningeal survival.
Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism
Posted inDermatology news Oncology

Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism

A large FAERS analysis links immune checkpoint inhibitors (ICIs) to markedly increased SJS/TEN risk, demonstrates additive synergy with high‑risk small molecules, and shows delayed latency particularly with anti–PD‑1 agents — supporting a two‑hit, T‑cell–mediated model and urging cautious coprescribing and prospective study.
Ezabenlimab plus mDCF Induction and Adaptive Chemoradiotherapy Achieve High Complete Response Rates in Stage 3 Squamous Cell Anal Carcinoma (INTERACT-ION)
Posted innews Oncology Radiology

Ezabenlimab plus mDCF Induction and Adaptive Chemoradiotherapy Achieve High Complete Response Rates in Stage 3 Squamous Cell Anal Carcinoma (INTERACT-ION)

The INTERACT-ION phase 2 trial reports that induction ezabenlimab with modified DCF followed by biomarker-guided, involved-node radiotherapy produced high clinical complete response rates (overall 77.8%) with a manageable safety profile in stage 3 anal squamous cell carcinoma.
Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis
Posted innews OB/GYN & Women's Health Oncology

Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis

The VENUSCANCER secondary analysis of 275,792 records from 103 population-based registries reveals wide global variation in stage at diagnosis, concordance with guideline-recommended initial treatments, and time to treatment for breast, cervical, and ovarian cancers — with consistent shortfalls in early detection in LMICs and marked intercountry variability in care.
Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma
Posted innews Oncology

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, though hematologic toxicity was substantial.